Please login to the form below

AZD3293

This page shows the latest AZD3293 news and features for those working in and with pharma, biotech and healthcare.

Biogen rises on more positive data for Alzheimer's candidate

compounds. Last week, it partnered with AstraZeneca (AZ) on MEDI1814, an antibody against amyloid-beta 42 (Aβ42) in phase I trials, and is also working with AZ on BACE inhibitor AZD3293,

Latest news

Lilly taps AstraZeneca for another anti-amyloid drug

The two companies are already working together on AZD3293, a BACE inhibitor which is designed to interrupt the formation of Aβ at an early stage in the process, and are running
Lilly sinks as solanezumab fails again in Alzheimer's

AZD3293. Ricks has previously suggested that if EXPEDITION3 was a bust then the expensive, 2, 500-patient prodromal trial will probably be abandoned.
AZ-Lilly start second pivotal trial of fast-tracked Alzheimer's drug

AstraZeneca and Eli Lilly's collaboration in Alzheimer's disease continues to make progress, as their AZD3293 drug is granted a fast-track review by the US FDA. ... AZ and Lilly are already carrying out one phase II/III placebo-controlled trial of AZD3293
Eisai and Biogen plan phase III trials for Alzheimer's drug

others. Merck has already started phase III trials of its MK-8931 candidate, while Lilly and AZ recently did likewise with AZD3293.
Lilly planning 20 new launches by 2023

Lilly's neuroscience R&D portfolio is headed by its Alzheimer's disease (AD) programmes, which include seven candidates headed by AstraZeneca-partnered BACE inhibitor AZD3293, and has recently started phase

More from news
Approximately 1 fully matching, plus 11 partially matching documents found.

Latest Intelligence

Deal Watch October 2016

Lilly. AZD3293. $500 profit share. Neurology 2012. Impax US. Zomig US.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Scientific Director: Great salary and bebefits

Editorial Director – Medical Education – Oxford: Negotiable

Account Manager – Med Comms – London: Salary TBC

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Editor – Medical Education Agency – Bucks: Salary TBC

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Medical Writer - (London, Brighton or Copenhagen): Competitive

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Senior Account Manager / Account Director: Great salary and bebefits

Senior Account Manager – Med Comms – Kent: Salary TBC

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Senior Account Manager or AD - Medical Communications: Salary TBC

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

Senior Programme Executive: Salary TBC

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Senior Medical Writer: Great salary and benefits

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

Senior Medical Writer: Great salary and bebefits

Subscribe to our email news alerts

PMHub

Add my company

Quintiles Medical Communications

Quintiles’ award-winning medical communications group sits at the heart of the enterprise. We offer a range of innovative strategic services,...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement: Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies: Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...